Filings & corporate actions
- 2 NovresultsResults · Q2 FY27 · consolidated and standalone-1.5%NSE
- 19 OctshareholdingShareholding · 30 Sept 2026-2.5%NSE
- 10 AugresultsResults · Q1 FY27 · consolidated and standalone-1.1%NSE
- 21 JulshareholdingShareholding · 30 Jun 2026-1.4%NSE
- 4 MayresultsResults · Q4 FY26 · consolidated and standalone+7.9%NSE
- 20 AprshareholdingShareholding · 31 Mar 2026+0.6%NSE
- 10 FebresultsResults · Q3 FY26 · consolidated and standalone+1.3%NSE
- 19 JanshareholdingShareholding · 31 Dec 2025-0.7%NSE
Reaction to results · all yearsrose on day 0 in 31 of 79 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q2 FY27 | 2 Nov 2026 | -1.5% | +7.1% | — | 1.9× |
| Q1 FY27 | 10 Aug 2026 | -1.1% | -3.7% | +15.2% | 1.6× |
| Q4 FY26 | 4 May 2026 | +7.9% | +10.2% | +45.5% | 27.4× |
| Q3 FY26 | 10 Feb 2026 | +1.3% | -1.1% | -7.5% | 4.8× |
| Q2 FY26 | 3 Nov 2025 | -3.4% | -3.8% | +0.1% | 1.4× |
| Q1 FY26 | 8 Aug 2025 | -0.6% | +1.4% | +6.0% | 0.9× |
| Q4 FY25 | 29 May 2025 | +8.8% | +11.8% | +21.8% | 6.0× |
| Q3 FY25 | 7 Feb 2025 | -3.1% | -16.1% | -23.7% | 1.0× |
| Q2 FY25 | 13 Nov 2024 | -1.6% | +8.9% | +28.7% | 0.8× |
| Q1 FY25 | 9 Aug 2024 | +3.0% | +2.8% | +8.8% | 2.4× |
| Q4 FY24 | 28 May 2024 | +0.6% | -7.1% | +16.9% | 2.2× |
| Q3 FY24 | 14 Feb 2024 | -1.0% | +26.4% | +16.0% | 0.6× |
| Q2 FY24 | 14 Nov 2023 | -1.5% | +16.5% | +42.4% | 4.6× |
| Q1 FY24 | 14 Aug 2023 | 0.0% | -4.6% | +3.3% | 0.4× |
| Q4 FY23 | 26 May 2023 | -1.7% | -2.3% | +34.5% | 0.6× |
| Q3 FY23 | 13 Feb 2023 | -2.6% | +0.4% | -10.9% | 1.3× |
| Q2 FY23 | 4 Nov 2022 | -0.1% | -0.9% | -4.6% | 0.7× |
| Q1 FY23 | 12 Aug 2022 | -2.3% | +8.2% | +16.6% | 1.1× |
| Q4 FY22 | 31 May 2022 | +2.4% | -0.7% | -18.9% | 0.5× |
| Q3 FY22 | 27 Jan 2022 | 0.0% | +0.2% | -13.6% | 0.5× |
| Q2 FY22 | 9 Nov 2021 | +1.1% | -1.3% | -6.3% | 1.2× |
| Q1 FY22 | 22 Jul 2021 | -0.4% | -3.8% | -22.2% | 0.5× |
| Q4 FY21 | 28 May 2021 | -2.4% | -2.9% | -16.2% | 0.8× |
| Q3 FY21 | 29 Jan 2021 | +0.6% | +5.5% | +4.0% | 0.5× |
| Q2 FY21 | 3 Nov 2020 | -1.6% | -2.1% | +50.0% | 1.6× |
| Q1 FY21 | 29 Aug 2020 | -5.0% | -9.7% | -14.7% | 0.7× |
| Q4 FY20 | 11 May 2020 | -4.9% | -17.0% | +1.1% | 1.4× |
| Q3 FY20 | 27 Jan 2020 | -2.1% | -2.7% | -3.9% | 5.9× |
| Q2 FY20 | 8 Nov 2019 | +0.2% | +0.7% | -16.7% | 0.5× |
| Q1 FY20 | 14 Aug 2019 | -2.2% | -11.7% | +11.4% | 0.8× |
| Q4 FY19 | 24 May 2019 | -0.2% | -2.1% | -5.1% | 0.6× |
| Q3 FY19 | 29 Jan 2019 | +0.9% | -7.6% | -12.0% | 1.4× |
| Q2 FY19 | 19 Nov 2018 | -2.6% | -1.9% | -1.2% | 0.7× |
| Q1 FY19 | 24 Aug 2018 | -1.9% | +1.5% | -13.9% | 0.8× |
| Q4 FY18 | 25 May 2018 | +1.9% | -4.2% | -2.1% | 0.6× |
| Q3 FY18 | 10 Feb 2018 | +0.8% | -5.7% | -1.8% | 0.8× |
| Q2 FY18 | 1 Nov 2017 | +0.5% | +10.2% | +10.4% | 0.9× |
| Q1 FY18 | 4 Aug 2017 | 0.0% | -5.8% | +2.1% | 0.6× |
| Q4 FY17 | 16 Jun 2017 | -6.7% | -7.3% | -1.2% | 3.7× |
| Q3 FY17 | 25 Jan 2017 | -3.1% | -2.5% | +3.2% | 1.3× |
| Q2 FY17 | 14 Nov 2016 | -3.0% | -12.1% | -12.0% | 0.9× |
| Q1 FY17 | 28 Sept 2016 | -4.5% | -0.5% | -3.7% | 2.5× |
| Q4 FY16 | 10 May 2016 | -1.4% | -0.4% | -0.1% | 0.6× |
| Q3 FY16 | 13 Feb 2016 | -0.5% | +6.4% | +28.3% | 2.5× |
| Q2 FY16 | 16 Nov 2015 | +0.3% | +5.5% | +3.0% | 0.8× |
| Q1 FY16 | 11 Aug 2015 | 0.0% | +1.2% | -28.2% | 1.2× |
| Q4 FY15 | 29 May 2015 | +2.0% | -9.1% | -4.4% | 0.6× |
| Q3 FY15 | 5 Feb 2015 | -3.7% | +16.4% | +31.9% | 2.4× |
| Q2 FY15 | 7 Nov 2014 | +4.3% | +4.5% | +34.0% | 2.0× |
| Q1 FY15 | 19 Aug 2014 | +1.7% | +0.7% | +21.0% | 0.7× |
| Q4 FY14 | 27 May 2014 | -4.5% | -14.9% | -19.7% | 0.8× |
| Q3 FY14 | 10 Feb 2014 | +3.5% | -1.9% | +10.1% | 2.3× |
| Q2 FY14 | 3 Nov 2013 | -1.5% | +6.0% | -11.2% | 0.4× |
| Q1 FY14 | 22 Aug 2013 | -1.4% | +7.7% | +36.6% | 0.7× |
| Q4 FY13 | 10 Jun 2013 | -10.0% | -7.3% | -24.0% | 0.2× |
| Q3 FY13 | 20 Feb 2013 | +1.3% | +2.5% | +3.4% | 1.2× |
| Q2 FY13 | 16 Nov 2012 | -2.1% | +0.7% | -9.5% | 0.6× |
| Q1 FY13 | 7 Aug 2012 | +2.4% | +17.5% | +21.2% | 1.3× |
| Q4 FY12 | 23 May 2012 | +12.7% | +11.5% | +23.2% | 17.4× |
| Q3 FY12 | 13 Feb 2012 | +4.7% | +10.5% | +28.4% | 6.0× |
| Q2 FY12 | 17 Nov 2011 | +0.2% | -2.0% | -21.4% | 1.0× |
| Q1 FY12 | 9 Aug 2011 | -5.9% | -13.8% | -12.0% | 2.0× |
| Q4 FY11 | 19 May 2011 | +5.6% | +0.9% | +9.8% | 7.9× |
| Q3 FY11 | 2 Feb 2011 | +5.0% | -8.4% | -8.6% | 5.2× |
| Q2 FY11 | 12 Nov 2010 | +10.8% | +7.3% | -4.9% | 4.7× |
| Q1 FY11 | 13 Aug 2010 | +17.6% | +52.7% | +72.1% | 12.3× |
| Q3 FY10 | 25 Jan 2010 | -4.3% | -2.3% | -15.6% | 0.6× |
| Q2 FY10 | 31 Oct 2009 | -5.1% | +5.8% | +3.7% | 1.2× |
| Q1 FY10 | 30 Jul 2009 | -4.7% | -1.4% | +10.1% | 1.1× |
| Q3 FY09 | 24 Apr 2009 | -5.4% | -14.1% | +19.3% | 0.4× |
| Q4 FY09 | 24 Apr 2009 | -5.4% | -14.1% | +19.3% | 0.4× |
| Q2 FY09 | 21 Oct 2008 | +0.8% | -11.9% | -36.1% | 1.1× |
| Q1 FY09 | 28 Jul 2008 | -2.5% | +1.5% | +3.9% | 0.8× |
| Q4 FY08 | 28 Apr 2008 | -2.4% | -0.2% | -4.2% | 3.1× |
| Q3 FY08 | 20 Feb 2008 | -1.4% | -4.2% | -27.0% | 0.6× |
| Q2 FY08 | 23 Oct 2007 | +0.6% | -0.2% | -3.3% | 3.5× |
| Q1 FY08 | 25 Jul 2007 | +3.3% | -2.4% | -4.5% | 2.0× |
| Q4 FY07 | 26 Apr 2007 | -2.3% | -4.3% | -1.6% | 0.9× |
| Q3 FY07 | 22 Feb 2007 | +0.8% | +13.4% | +16.0% | 2.9× |
| Average | -0.2% | +0.4% | +3.7% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q2 FY27
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +12.8% | +10.6% | +7.7% | +3.8% | +4.6% | +0.2% |
| Profit | — | — | — | — | -10.9% | — |
Key data
Delivery percentage
Over the last 20 sessions WOCKPHARMA settled 37.1% of its traded quantity, which is ordinary for an NSE equity. That is in line with its own one-year average of 36.8%. The latest session ranks higher than 60% of the 3,504 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
Dividends, deals & holders
Performance returns
| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -0.12% | +7.75% | +17.73% | +19.33% | +36.54% | +62.35% |
Valuation
Ownership
Quarterly results · consolidated
| Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 888.0 | 965.0 | 929.0 | 969.0 |
| YoY chg | +23.2% | +29.9% | +25.9% | +23.9% |
| Net profit (₹ Cr) | 61.0 | 164.0 | 107.0 | 73.0 |
| YoY chg | +205.0% | — | — | -11.0% |
| Net margin | 6.9% | 17.0% | 11.5% | 7.5% |
| EPS | 3.61 | 10.22 | 6.55 | 4.85 |
Shareholding over time
By quarter
30 Sept 2026 · promoter 49.32% · public 50.68%- Promoter
- Public and others
- Promoter
- 49.32%
- Public
- 50.68%
- Promoter change
- +0.24 pp
- Filed
- 19 Oct 2026
- FII
- —
- DII
- —
- Promoter pledged
- —
Who the public is
- Mutual funds
- —
- Insurance
- —
- FPI
- —
- Retail ≤ ₹2L
- —
- HNI > ₹2L
- —
- NRI
- —
- Bodies corporate
- —
- Shareholders
- —
Major holders
As of 30 Jun 2026| Holder | Type | Holding | Shares |
|---|---|---|---|
| Themisto Trustee Company Private Limited | Promoter · Other | 40.15% | 6.52Cr |
| Pasithee Trustee Company Private Limited | Promoter · Other | 2.72% | 44.20L |
| Ananke Trustee Company Private Limited | Promoter · Other | 2.35% | 38.11L |
| Tata Mutual Fund - Tata Small Cap Fund | Mutual fund | 2.03% | 33.02L |
| Callirhoe Trustee Company Private Limited | Promoter · Other | 1.92% | 31.12L |
| Rekha Jhunjhunwala | Individual | 1.75% | 28.37L |
| Hsbc Mutual Fund - Hsbc Small Cap Fund | Mutual fund | 1.30% | 21.19L |
| 3p India Equity Fund 1 | AIF | 1.15% | 18.62L |
| Callirhoe Trustee Company Private Limited | Promoter · Other | 0.58% | 9.37L |
| Pasithee Trustee Company Private Limited | Promoter · Other | 0.40% | 6.50L |
Every promoter-group member, and each public holder above 1%, as filed.
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.
Dividends
| Financial year | Payments | Declared | Adjusted |
|---|---|---|---|
| FY2016-17 | 1 | ₹10.00 | ₹10.00 |
| FY2014-15 | 1 | ₹20.00 | ₹20.00 |
| FY2013-14 | 3 | ₹15.00 | ₹15.00 |
| Ex-date | Record date | Declared | Adjusted |
|---|---|---|---|
| 17 Nov 2016 | — | ₹10.00 | ₹10.00 |
| 13 Nov 2014 | — | ₹20.00 | ₹20.00 |
| 17 Feb 2014 | — | ₹5.00 | ₹5.00 |
| 7 Nov 2013 | — | ₹5.00 | ₹5.00 |
| 22 Aug 2013 | — | ₹5.00 | ₹5.00 |
Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.
Insider trades
- Insiders net, 30d
- ₹0
- Insiders net, 90d
- ₹0
- Promoters net, 90d
- ₹0
- Insider buyers, 90d
- 0
- Last promoter buy
- 9.6 years ago
- Disclosures on record
- 203
| Broadcast | Person | Side | Shares | Value | Price | Holding before → after | Stake | Regulation |
|---|---|---|---|---|---|---|---|---|
| 1 Sept 2021 | Ananke Trustee Company Private LimitedPromoter | Sell | 3.00L | ₹12.0Cr | 399.11 | 9.73L → 6.73L | 0.61%-0.27 pp | 7(2)told 30 Aug 2021 |
| 1 Sept 2021 | Pasithee Trustee Company Private LimitedPromoter | Sell | 5.00L | ₹20.3Cr | 405.90 | 10.00L → 5.00L | 0.45%-0.45 pp | 7(2)told 30 Aug 2021 |
| 1 Sept 2021 | Themisto Trustee Company Private LimitedPromoter | Sell | 5.00L | ₹22.1Cr | 441.42 | 38.00L → 33.00L | 2.98%-0.45 pp | 7(2)told 30 Aug 2021 |
| 1 Sept 2021 | Themisto Trustee Company Private LimitedPromoter | Sell | 5.00L | ₹21.6Cr | 432.64 | 6.00Cr → 5.95Cr | 53.69%-0.45 pp | 7(2)told 30 Aug 2021 |
| 31 Aug 2021 | Akhilesh GuptaDirector | Buy | 10.0K | ₹43.9L | 439.33 | — → 10.0K | 0.01% | 7(2)told 27 Aug 2021 |
| 2 Jul 2021 | Callirhoe Trustee Company Private LimitedPromoter | Sell | 1.00L | ₹5.2Cr | 519.00 | 8.21L → 7.21L | 0.65%-0.09 pp | 7(2)told 1 Jul 2021 |
| 2 Jul 2021 | Themisto Trustee Company Private LimitedPromoter | Sell | 5.00L | ₹26.3Cr | 526.60 | 43.00L → 38.00L | 3.43%-0.45 pp | 7(2)told 1 Jul 2021 |
| 28 Jun 2021 | Callirhoe Trustee Company Private LimitedPromoter | Sell | 5.00L | ₹27.7Cr | 553.00 | 13.21L → 8.21L | 0.74%-0.45 pp | 7(2)told 28 Jun 2021 |
| 28 Jun 2021 | Themisto Trustee Company Private LimitedPromoter | Sell | 1.00L | ₹5.4Cr | 539.00 | 44.00L → 43.00L | 3.88%-0.09 pp | 7(2)told 28 Jun 2021 |
| 28 Jun 2021 | Ananke Trustee Company Private LimitedPromoter | Sell | 5.00L | ₹27.9Cr | 558.60 | 14.73L → 9.73L | 0.88%-0.45 pp | 7(2)told 25 Jun 2021 |
| 28 Jun 2021 | Pasithee Trustee Company Private LimitedPromoter | Sell | 5.00L | ₹28.7Cr | 573.00 | 15.00L → 10.00L | 0.90%-0.45 pp | 7(2)told 25 Jun 2021 |
| 28 Jun 2021 | Themisto Trustee Company Private LimitedPromoter | Sell | 5.00L | ₹29.5Cr | 590.00 | 6.05Cr → 6.00Cr | 54.16%-0.45 pp | 7(2)told 25 Jun 2021 |
| 15 Jun 2021 | Mahesh PatelEmployee | Sell | 10.0K | ₹66.1L | 660.90 | 61.8K → 51.8K | 0.05%-0.01 pp | 7(2)told 14 Jun 2021 |
| 15 Jun 2021 | Mahesh PatelEmployee | Sell | 20.0K | ₹1.3Cr | 657.18 | 81.8K → 61.8K | 0.06%-0.02 pp | 7(2)told 14 Jun 2021 |
| 16 Mar 2021 | Debolina PartapEmployee | Sell | 7.0K | ₹34.2L | 489.26 | 15.6K → 8.6K | 0.01%-0.01 pp | 7(2)told 15 Mar 2021 |
| 19 Feb 2021 | Ajay SahniEmployee | Sell | 2.5K | ₹13.0L | 520.99 | 3.3K → 800 | 0.00%0.00 pp | 7(2)told 17 Feb 2021 |
| 14 Dec 2020 | Mahesh PatelEmployee | Sell | 3.0K | ₹16.1L | 536.37 | 78.8K → 75.8K | 0.07%-0.00 pp | 7(2)told 14 Dec 2020 |
| 2 Jan 2020 | Themisto Trustee Company Private LimitedPromoter | Sell | 5.98L | ₹14.4Cr | 241.04 | 49.98L → 44.00L | 3.97%-0.54 pp | 7(2)told 31 Dec 2019 |
| 27 Nov 2019 | Pasithee Trustee Company Private LimitedPromoter | Sell | 3.00L | ₹8.5Cr | 282.70 | 18.00L → 15.00L | 1.35%-0.27 pp | 7(2)told 22 Nov 2019 |
| 27 Nov 2019 | Callirhoe Trustee Company Private LimitedPromoter | Sell | 4.79L | ₹12.6Cr | 263.69 | 18.00L → 13.21L | 1.19%-0.43 pp | 7(2)told 22 Nov 2019 |
| 27 Nov 2019 | Themisto Trustee Company Private LimitedPromoter | Sell | 4.02L | ₹11.3Cr | 280.54 | 54.00L → 49.98L | 4.51%-0.36 pp | 7(2)told 22 Nov 2019 |
| 27 Nov 2019 | Ananke Trustee Company Private LimitedPromoter | Sell | 3.27L | ₹9.0Cr | 274.77 | 18.00L → 14.73L | 1.33%-0.30 pp | 7(2)told 22 Nov 2019 |
| 16 May 2019 | Mahesh PatelEmployee | Sell | 2.0K | ₹7.4L | 368.53 | 74.8K → 72.8K | 0.07%-0.00 pp | 7(2)told 15 May 2019 |
| 16 May 2019 | Ravindra D YeoleEmployee | Sell | 1.3K | ₹4.8L | 371.23 | 4.5K → 3.2K | 0.00%0.00 pp | 7(2)told 14 May 2019 |
| 29 Mar 2019 | Ajay SahniOther | Sell | 1.5K | ₹6.5L | 434.17 | 2.4K → 900 | 0.00%0.00 pp | 7(2)told 27 Mar 2019 |
| 6 Feb 2019 | Jerry SaidanhaEmployee | Sell | 3.0K | ₹12.6L | 418.99 | 28.1K → 25.1K | 0.02%-0.00 pp | 7(2)told 6 Feb 2019 |
SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.
How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session
Bulk & block deals · 6 May 2026
CSV| Date | Deal | Client | Quantity | Price | Value |
|---|---|---|---|---|---|
| 6 May 2026 | Sell · bulk | NK SECURITIES RESEARCH PRIVATE LIMITED | 10.10L | 1,720.71 | ₹173.7Cr |
| 6 May 2026 | Buy · bulk | NK SECURITIES RESEARCH PRIVATE LIMITED | 10.10L | 1,720.00 | ₹173.7Cr |
| 1 Jan 2024 | Buy · bulk | GRAVITON RESEARCH CAPITAL LLP | 8.45L | 456.76 | ₹38.6Cr |
| 1 Jan 2024 | Sell · bulk | GRAVITON RESEARCH CAPITAL LLP | 8.45L | 456.72 | ₹38.6Cr |
| 12 Dec 2023 | Sell · bulk | GRAVITON RESEARCH CAPITAL LLP | 9.80L | 397.26 | ₹38.9Cr |
| 12 Dec 2023 | Buy · bulk | GRAVITON RESEARCH CAPITAL LLP | 9.80L | 397.13 | ₹38.9Cr |
| 11 Dec 2023 | Buy · bulk | GRAVITON RESEARCH CAPITAL LLP | 9.16L | 373.22 | ₹34.2Cr |
| 11 Dec 2023 | Sell · bulk | GRAVITON RESEARCH CAPITAL LLP | 9.16L | 372.83 | ₹34.2Cr |
| 17 Nov 2023 | Sell · bulk | GRAVITON RESEARCH CAPITAL LLP | 11.48L | 325.17 | ₹37.3Cr |
| 17 Nov 2023 | Buy · bulk | GRAVITON RESEARCH CAPITAL LLP | 11.48L | 324.81 | ₹37.3Cr |
| 16 Nov 2023 | Buy · bulk | GRAVITON RESEARCH CAPITAL LLP | 18.08L | 307.02 | ₹55.5Cr |
| 16 Nov 2023 | Sell · bulk | GRAVITON RESEARCH CAPITAL LLP | 18.08L | 307.00 | ₹55.5Cr |
A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.
Takeover-code disclosures
Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.
Every stock on this session →Short selling, lending & margin
Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.
Exchange surveillance
- P/E > 50 (4 quarters) · since 5 May 2026 — P/E above 50 on the last four quarters’ earnings.
Price band: 20% · not in the F&O ban · 20.4% of the market-wide position limit used.
From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes · ban days · MWPL.
Every stock on this session →Futures & options · 27 Jun 2019
CSVLong unwinding — price down as positions closed — longs exiting.
- Futures OI
- 2.59L
- OI change
- -68.14%
- Basis
- -2.06%
- Rollover
- 0.0%
- PCR (OI)
- 0.82
- PCR (volume)
- 1.24
- Front settle
- 376.05
- Lot size
- —
- Futures volume
- 2.0K
- Futures trades
- —
- Futures value
- ₹68.7Cr
- Sessions shown
- 250
₹9.7Cr
shares
contracts
Open interest is in shares (index units for an index), summed over every expiry; volume, trades and traded value too. Settle and lot size are the front future’s. Buildup compares the close’s direction with the change in futures OI across the contracts still open, so an expiring contract does not read as unwinding. Scan it with pattern is long_buildup.
Financials · quarterly statement
| Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Q2 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 701.0 | 700.0 | 739.0 | 809.0 | 721.0 | 743.0 | 738.0 | 782.0 | 888.0 | 965.0 | 929.0 | 969.0 | |
| Other income | 8.0 | 54.0 | 30.0 | 9.0 | 8.0 | 15.0 | 20.0 | 21.0 | 25.0 | 45.0 | 31.0 | 11.0 | |
| Total income | 709.0 | 754.0 | 769.0 | 818.0 | 729.0 | 758.0 | 758.0 | 803.0 | 913.0 | 1,010.0 | 960.0 | 980.0 | |
| Total expenses | 796.0 | 934.0 | 775.0 | 827.0 | 708.0 | 780.0 | 770.0 | 712.0 | 836.0 | 843.0 | 844.0 | 907.0 | |
| └ Finance costs | 77.0 | 73.0 | 73.0 | 73.0 | 60.0 | 48.0 | 48.0 | 55.0 | 60.0 | 50.0 | 52.0 | 56.0 | |
| └ Depreciation | 55.0 | 58.0 | 54.0 | 55.0 | 55.0 | 53.0 | 56.0 | 53.0 | 65.0 | 53.0 | 55.0 | 55.0 | |
| Profit before tax | (87.0) | (180.0) | (6.0) | (9.0) | 21.0 | (22.0) | (109.0) | 91.0 | 67.0 | 189.0 | 116.0 | 73.0 | |
| Tax expense | (1.0) | (3.0) | 10.0 | 7.0 | 1.0 | 23.0 | (1.0) | 9.0 | 6.0 | 25.0 | 9.0 | 0.0 | |
| Net profit | (86.0) | (177.0) | (16.0) | (16.0) | 20.0 | (45.0) | (108.0) | 82.0 | 61.0 | 164.0 | 107.0 | 73.0 | |
| EPS | -5.75 | -11.64 | -0.95 | -1.47 | 0.91 | -1.57 | -5.53 | 4.81 | 3.61 | 10.23 | 6.55 | 4.85 | |
| Net margin | -12.27% | -25.29% | -2.17% | -1.98% | 2.77% | -6.06% | -14.63% | 10.49% | 6.87% | 16.99% | 11.52% | 7.53% | |
| PBT margin | -12.41% | -25.71% | -0.81% | -1.11% | 2.91% | -2.96% | -14.77% | 11.64% | 7.55% | 19.59% | 12.49% | 7.53% | |
| Tax rate | — | — | — | — | 4.76% | — | — | 9.89% | 8.96% | 13.23% | 7.76% | 0.00% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 2 Nov 2026.
Balance sheet & cash flow · half-yearly
Balance sheet
| FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 7,683.0 | 7,420.0 | 7,649.0 | 7,588.0 | 8,135.0 | 8,533.0 | 8,615.0 | 8,902.0 | |
| Current assets | 1,914.0 | 1,739.0 | 2,073.0 | 1,904.0 | 2,465.0 | 2,701.0 | 2,606.0 | 2,764.0 | |
| └ Cash & equivalents | 90.0 | 54.0 | 505.0 | 143.0 | 112.0 | 177.0 | 217.0 | 330.0 | |
| └ Other bank balances | 34.0 | 30.0 | 24.0 | 32.0 | 79.0 | 57.0 | 33.0 | 233.0 | |
| └ Current investments | 0.0 | 0.0 | 0.0 | 48.0 | 422.0 | 696.0 | 412.0 | 117.0 | |
| └ Trade receivables | 797.0 | 714.0 | 618.0 | 695.0 | 661.0 | 536.0 | 588.0 | 632.0 | |
| └ Inventories | 658.0 | 635.0 | 640.0 | 657.0 | 725.0 | 866.0 | 887.0 | 973.0 | |
| Total equity | 3,662.0 | 3,432.0 | 3,662.0 | 3,713.0 | 4,657.0 | 4,876.0 | 5,281.0 | 5,500.0 | |
| └ Attributable to owners | 3,354.0 | 3,125.0 | 3,359.0 | 3,395.0 | 4,353.0 | 4,567.0 | 4,940.0 | 5,158.0 | |
| └ Non-controlling interest | 308.0 | 307.0 | 303.0 | 318.0 | 304.0 | 309.0 | 341.0 | 342.0 | |
| └ Share capital | 72.0 | 72.0 | 77.0 | 77.0 | 81.0 | 81.0 | 81.0 | 81.0 | |
| Borrowings | 1,887.0 | 2,003.0 | 2,112.0 | 2,154.0 | 1,859.0 | 2,323.0 | 2,125.0 | 2,150.0 | |
| └ Current | 1,663.0 | 1,035.0 | 1,221.0 | 935.0 | 648.0 | 654.0 | 607.0 | 719.0 | |
| └ Non-current | 224.0 | 968.0 | 891.0 | 1,219.0 | 1,211.0 | 1,669.0 | 1,518.0 | 1,431.0 | |
| Trade payables | 867.0 | 800.0 | 766.0 | 677.0 | 592.0 | 587.0 | 563.0 | 623.0 | |
| Current liabilities | 3,435.0 | 2,685.0 | 2,791.0 | 2,380.0 | 2,042.0 | 1,736.0 | 1,622.0 | 1,785.0 | |
| Total liabilities | 4,021.0 | 3,988.0 | 3,987.0 | 3,875.0 | 3,478.0 | 3,657.0 | 3,334.0 | 3,402.0 | |
| Net debt | 1,763.0 | 1,919.0 | 1,583.0 | 1,931.0 | 1,246.0 | 1,393.0 | 1,463.0 | 1,470.0 | |
| Debt / equity | 0.52 | 0.58 | 0.58 | 0.58 | 0.40 | 0.48 | 0.40 | 0.39 | |
| Current ratio | 0.56 | 0.65 | 0.74 | 0.80 | 1.21 | 1.56 | 1.61 | 1.55 |
Cash flow, year to date
| FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 153.0 | 104.0 | 219.0 | 32.0 | (22.0) | 189.0 | 390.0 | 237.0 | |
| └ Capex | (42.0) | (94.0) | (59.0) | (203.0) | (365.0) | (197.0) | (364.0) | (238.0) | |
| Free cash flow | 111.0 | 10.0 | 160.0 | (171.0) | (387.0) | (8.0) | 26.0 | (1.0) | |
| Investing cash flow | (125.0) | (88.0) | (137.0) | (247.0) | (783.0) | (417.0) | (241.0) | (2.0) | |
| Financing cash flow | (315.0) | (50.0) | 334.0 | (147.0) | 409.0 | 297.0 | (54.0) | (123.0) | |
| └ Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Buybacks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net change in cash | (280.0) | (34.0) | 415.0 | (362.0) | (393.0) | 69.0 | 95.0 | 112.0 |
From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.
Announcements & board meetings
As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.
Every stock on this session →WOCKPHARMA at a glance
- WOCKPHARMA closed at ₹2,184.4 on 20 Nov 2026, -0.12% on the day, +62.3% over one year, 9.8% below its 52-week high of ₹2,422.3.
- Delivery was 32.9% of traded quantity on 20 Nov 2026, the 60th percentile of its own 3,504 sessions with a reading (20-session average 37.1%, 1-year average 36.8%).
- Market capitalisation is ₹35,495 crore at a trailing P/E of 86.6 (trailing EPS ₹25.23).
- Q2 FY27 results (consolidated, filed 2 Nov 2026): revenue ₹969 crore (+23.9% year on year), net profit ₹73 crore (-11.0%); the price moved -1.5% on the first session after.
- Promoters held 49.32% at 30 Sept 2026, up 0.24 percentage points on the previous filing.
- Q3 FY27 results are expected between 27 Jan 2027 and 14 Feb 2027, going by past filing dates — an estimate, not an announcement.
About
Sector history
- to 16 Aug 2026Index industry · Healthcare
- from 16 Aug 2026Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
NSE’s own classification, by the snapshot it changed on.
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.
More in Pharmaceuticals & Biotechnology
- DIDIVISLABDivi's Laboratories Limited11,180.50+0.02%
- LALAURUSLABSLaurus Labs Limited2,294.60-0.49%
- SUSUNPHARMASun Pharmaceutical Industries Limited1,884.90-0.79%
- ACACUTAASAcutaas Chemicals Limited3,833.50-3.61%
- SASAILIFESai Life Sciences Limited1,800.70+0.69%
- PPPPLPHARMAPiramal Pharma Limited239.30-0.15%
- DRDRREDDYDr. Reddy's Laboratories Limited1,390.20-0.76%
- GLGLENMARKGlenmark Pharmaceuticals Limited2,648.00+1.51%
- AUAUROPHARMAAurobindo Pharma Limited1,799.00-0.37%
- CICIPLACipla Limited1,415.00-0.25%
- ZYZYDUSLIFEZydus Lifesciences Limited1,200.00-0.24%
- MAMANKINDMankind Pharma Limited2,665.00+1.37%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE